Investigators presented an abstract on real-world clinical and anatomical outcomes from the VOYAGER Study at Euretina 2024 at the end of September.

As a global prospective non-interventional study, VOYAGER evaluated the real-world efficacy and safety of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Conducted in 20 countries with 298 patients, the study evaluated clinical outcomes over a 3-month period. Patients received an average of 2.8 (nAMD) and 2.9 (DME) injections.

Mean visual acuity increased by +4.4 letters in nAMD and +5.7 letters in DME patients, measured using ETDRS letters. Mean central subfield thickness decreased by -82.0 µm in nAMD patients and -106.4 µm in DME patients by month 3. In nAMD eyes, subretinal fluid decreased from 70.6% to 11.7%, while intraretinal fluid dropped from 50.6% to 21.9% at month 3. In DME, subretinal fluid reduced from 24.3% to 6%, and intraretinal fluid decreased from 89.7% to 78.3%. The researchers reported that safety outcomes were consistent with pivotal Phase 3 trials.

The VOYAGER study will continue over 5 years to “provide insights on clinical and anatomical outcomes in patients initiating faricimab treatment in routine clinical practice.”

The presented abstract from Euretina 2024 and a full list of author disclosures can be found here.